Guggenheim Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Guggenheim Capital’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,893	Closed	-$6K	–	2899
2017 Q1	$6K	Buy	+1,893	New	+$8.95K	﹤0.01%	2832
2016 Q1	–	Sell	-3,081	Closed	-$114K	–	3043
2015 Q4	$114K	Buy	+3,081	New	+$136K	﹤0.01%	2829
2013 Q3	–	Sell	-712	Closed	-$21K	–	3224
2013 Q2	$21K	Buy	+712	New	+$26.6K	﹤0.01%	2983

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Guggenheim Capital's ANTH Position: Q2 2017 in Review

Guggenheim Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 1,893 shares — an estimated $6K sold.

Guggenheim Capital first reported a position in ANTH in Q2 2013 and held it in 3 quarters. The position peaked at $114K in Q4 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

Guggenheim Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Guggenheim Capital sold 1,893 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $6K.
Guggenheim Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 3 quarters.
Guggenheim Capital's Anthera Pharmaceuticals, Inc. position peaked at $114K in Q4 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Guggenheim Capital's 13F filing for Q2 2017, filed 14 Aug 2017.